Valuation : Sionna Therapeutics, Inc.

Market Cap 345M 297M 281M 255M 478M 32.92B 481M 3.34B 1.28B 16.73B 1.29B 1.27B 52.9B P/E 2026 *
-3.25x
P/E 2027 * -3.33x
Enterprise Value 198M 171M 162M 147M 275M 18.95B 277M 1.92B 739M 9.63B 745M 729M 30.46B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.16%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Sionna Therapeutics, Inc.

1 day+3.02%
1 week+16.30%
Current month+30.18%
1 month+74.44%
3 months-76.93%
6 months-79.39%
Current year-80.92%
1 week 6.89
Extreme 6.89
8.03
1 month 4.98
Extreme 4.975
8.03
Current year 4.01
Extreme 4.01
54.97
1 year 4.01
Extreme 4.01
54.97
3 years 4.01
Extreme 4.01
54.97
5 years 4.01
Extreme 4.01
54.97
10 years 4.01
Extreme 4.01
54.97
Manager TitleAgeSince
Corporate Officer/Principal - 2019-07-31
Corporate Officer/Principal - 2019-07-31
Chief Executive Officer 55 2021-04-30
Director TitleAgeSince
Director/Board Member 51 2019-11-30
Director/Board Member 44 2019-11-30
Director/Board Member 52 2020-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/7/26
OrbiMed Advisors Private Equity
SellCompany -85,918 0.1903%
7/7/26
OrbiMed Advisors Private Equity
SellCompany -85,918 0.1903%
7/6/26 Exercice

General Counsel

30,750 0.0681%
Change 5-day change 1-year change 3-year change Capi.($)
+3.02%+16.30%-66.55% - 345M
-0.71%-8.73%-4.56%+9.80% 46.05B
+0.21%-3.37%+403.76%+534.40% 43.59B
+1.74%-3.63%+42.37%+22.59% 42.35B
+1.38%-4.46%+10.38%+79.88% 38.86B
-1.44%-4.76%+10.26%+38.52% 32.24B
+0.87%-2.81% - - 17.16B
+0.75%-0.99%+23.25%+116.71% 16.28B
-0.31%-3.76%+12.33%+30.49% 14.32B
+1.93%-5.14%+81.55%+39.31% 13.03B
Average +0.74%-2.99%+56.97%+108.96% 26.42B
Weighted average by Cap. +0.40%-5.08%+87.07%+129.28%

Financials

2026 *2027 *
Net sales - -
Net income -112M -96.89M -91.69M -83.06M -156M -10.73B -157M -1.09B -419M -5.46B -422M -413M -17.25B -116M -100M -94.64M -85.73M -161M -11.08B -162M -1.12B -432M -5.63B -435M -426M -17.81B
Net Debt -146M -126M -119M -108M -203M -13.96B -204M -1.42B -544M -7.1B -549M -537M -22.44B -183M -158M -149M -135M -254M -17.47B -255M -1.77B -681M -8.88B -687M -671M -28.07B
Logo Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on researching and developing novel medicines for cystic fibrosis. It is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). It is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. It is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
Employees
59
Date Price Change Volume
26-09-11 US$7.850 +3.02% 1,207,555
26-09-10 US$7.620 +1.87% 1,222,717
26-09-09 US$7.480 +2.47% 767,459
26-09-08 US$7.300 +1.67% 884,751
26-09-04 US$7.180 +6.37% 926,065
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
7.620USD
Average target price
20.86USD
Spread / Average Target
+173.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SION Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!